Company Filing History:
Years Active: 2025
Title: Mahmoud Rashed: Innovator in CNS Disorder Treatments
Introduction
Mahmoud Rashed is a notable inventor based in Cairo, Egypt. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of central nervous system (CNS) disorders. His innovative work focuses on developing compounds that can modulate GPR17, a receptor implicated in various CNS diseases.
Latest Patents
Mahmoud Rashed holds a patent for N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis. The patent discloses N-(phenyl)-1H-indole-3-sulfonamide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives, which are substituted at the 1- and 6-positions of the respective moieties. These compounds exhibit GPR17 modulating properties that are beneficial for treating or preventing a variety of CNS diseases, particularly myelinating disorders like multiple sclerosis.
Career Highlights
Mahmoud Rashed is currently associated with Ucb Pharma GmbH, where he continues to advance his research in CNS disorders. His work has garnered attention for its potential to improve treatment options for patients suffering from debilitating conditions.
Collaborations
He collaborates with esteemed colleagues such as Cécile Pegurier and Silvia Lovera, contributing to a dynamic research environment focused on innovative solutions for CNS disorders.
Conclusion
Mahmoud Rashed's contributions to the field of pharmaceuticals, particularly through his patent on GPR17 modulators, highlight his role as an innovator in the treatment of CNS disorders. His ongoing work at Ucb Pharma GmbH promises to further enhance therapeutic options for patients in need.